Iranian Company Makes ‘Coageight’ Drug for Hemophilia Patients
“Recently, a knowledge-based company has succeeded in producing the Coageight drug for hemophilia patients which is the second source of production of factor 8 medicine and can settle part of the problems of medicine shortage in Iran,” Ahmad Qavidel, an advisor to the managing-director of Iran’s hemophilia center, told ANA.
He added that the Iranian Food and Drug Organization has promised to import 10% to 15% of the hemophilia patients' needs in order to supply the factor VIII drug, so that the country does not face an acute medicine problem when in need.
Factor VIII is a protein produced naturally in the body and is necessary for the blood to form clots and stop bleeding.
Coageight is a medicine used for the treatment and prevention of bleeding in all age groups of patients with haemophilia A (inherited bleeding disorder caused by factor VIII deficiency).
It is produced by recombinant DNA technology in a Chinese Hamster Ovary (CHO) cell line without the addition of any exogenous human- or animal-derived protein in the cell culture process, purification or final formulation.
In patients with haemophilia A, factor VIII is missing or not working properly. Coageight is used to replace the missing or deficient factor VIII. It increases factor VIII level in the blood and temporarily corrects the bleeding tendency.
4155/v
